



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Estimation of Intestinal Fatty Acid Binding Protein Level as a Marker of Gut Failure in Critically ILL Pediatric Patients

Thesis

*Submitted for Partial Fulfilment of
Master Degree in **Pediatrics***

By

Christina Eskander Hermina
M.B.B.Ch

Under Supervision of

Prof. Dr. Hanan Mohamed Ibrahim

*Professor of Pediatrics
Faculty of Medicine – Ain Shams University*

Dr. Sondos Mohamed Magdy

*Lecturer of Pediatric
Faculty of Medicine – Ain Shams University*

Dr. Yasser Wagih Darwich

*Consultant of Clinical Pathology
Faculty of Medicine – Ain Shams University*

Faculty of Medicine - Ain Shams University

2020

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Hanan Mohamed Ibrahim**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Dr. Sondos Mohamed Magdy**, Lecturer of Pediatric, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. Yasser Wagih Darwich**, Consultant of Clinical Pathology, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.*

Last but not least, this work is dedicated to all our patients, without them, this work would have been of no value, and also to my colleagues for their support and care in every step of my career.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Christina Eskander Hermina

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	v
List of Abbreviations.....	vii
Introduction	- 1 -
Aim of the Work	5
Review of Literature	
▪ Sepsis	6
▪ Lactoferrin	31
▪ Gut Failure	39
▪ Intestinal Fatty Acid Binding Protein.....	60
Patients and Methods.....	68
Results.....	75
Discussion	105
Summary	124
Conclusion	127
Recommendations	128
References	129
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Sepsis associated organ dysfunction criteria	8
Table 2:	Pediatric sequential organ failure assessment score	9
Table 3:	qSOFA was defined as a score composed of three binary variables (tachypnoea, altered mentation, hypotension)	10
Table 4:	Emerging biomarkers of pediatric sepsis	27
Table 5:	Causes of intestinal failure in children	51
Table 6:	Gastrointestinal failure score	53
Table 7:	Pediatric sequential organ failure assessment score	53
Table 8:	Factors associated with prognosis of intestinal failure.....	56
Table 9:	Signs of enteral feeding intolerance, considerations, diagnostic/therapeutic strategies.	58
Table 10:	Types of fatty acid binding proteins	63
Table 11:	Sequential (sepsis-related) organ failure assessment score	70
Table 12:	GIF score.....	72
Table 13:	Standard dilution	73
Table 14:	Comparison between patients group and control group as regards demographic data.	75

List of Tables cont...

Table No.	Title	Page No.
Table 15:	Comparison between patients group and control group as regards serum IFABP level on day one and serum IFABP level on day 10.....	76
Table 16:	Comparison between patients receiving lactoferrin and patients not receiving it as regards clinical data on day one.	79
Table 17:	SOFA, GIF scores results and laboratory data results among patients who received lactoferrin and patients who didn't receive it on day one of the study.	80
Table 18:	Liver, kidney functions test, ABG, serum CRP level and serum lactate level among patients receiving lactoferrin and patients who did not on day one of the study.	81
Table 19:	IFABP level among patients receiving lactoferrin and patients who did not on day one of the study.	82
Table 20:	Comparison between patients receiving lactoferrin and patients not receiving it as regards clinical data on day ten.....	83
Table 21:	SOFA, GIF scores results and laboratory data results among patients who received lactoferrin and patients who didn't receive it on day ten of the study.	84
Table 22:	Liver, kidney functions test, ABG, serum CRP level, and serum lactate level among patients receiving lactoferrin and patients who did not on day ten (D10) of the study.	85

List of Tables cont...

Table No.	Title	Page No.
Table 23:	IFABP level among patients receiving lactoferrin and patients who did not on day ten (D10) of the study.....	87
Table 24:	Fate of patients receiving lactoferrin and patients who not receiving.	88
Table 25:	Comparison of clinical data on day one (D1) and day ten (D10) among patients who are receiving lactoferrin.	89
Table 26:	SOFA, GIF scores results and laboratory data results among patients who are receiving lactoferrin on day one (D1) and day ten (D10) of the study.....	90
Table 27:	Liver, kidney functions test, ABG, serum CRP level and serum lactate level among patients who are receiving lactoferrin on day one (D1) and day ten (D10) of the study.	92
Table 28:	Serum IFABP level among patients who are receiving lactoferrin on day one (D1) and day ten (D10) of the study.....	94
Table 29:	Comparison between survivors patients and non survivors as regards demographic data.	94
Table 30:	Comparison between survivors group and non-survivors group as regards clinical data in day one of the study (D1).....	95
Table 31:	Comparison between survivors and non-survivors patients as regards SOFA, GIF scores results and laboratory data results on day one of the study.	96

List of Tables cont...

Table No.	Title	Page No.
Table 32:	Comparison between survivors and non-survivors as regards liver and kidney functions test, ABG, serum CRP, serum IFABP and serum lactate on day one of the study (D1).	98
Table 33:	Comparison between survivors and non-survivors as regards serum IFABP on day one of the study (D1).	100
Table 34:	Relation between GIF score result and fate	101
Table 35:	Comparison between survivors and non-survivors as regards culture and sensitivity results.	102
Table 36:	Correlation between serum IFABP results on day one and day 10 of the study and other demographic, SOFA score, GIF score and laboratory findings on day one	103
Table 37:	Receiver-operating characteristic (ROC) curve analysis for prediction of mortality using SOFA score and serum IFABP level results on day one of the study.	104

List of Figures

Fig. No.	Title	Page No.
Figure 1:	The effect of endotoxin on macrophage release of mediators of inflammation.	18
Figure 2:	Effect of exotoxin (superantigen) on release of mediators of inflammation.	18
Figure 3:	Pathogenesis of sepsis and multiple organ dysfunction syndrome (MODS)	19
Figure 4:	Clinical use of biomarkers in pediatric sepsis	27
Figure 5:	Surviving sepsis campaign pediatric treatment protocol	28
Figure 6:	Crystal structures of (A) bovine lactoferrin (PDB code =1BLF), (B) human lactoferrin (1B0L).....	32
Figure 7:	Events occurring as the normal intestinal barrier becomes impaired in sepsis, ischemia and other harmful conditions	41
Figure 8:	“Three hit model” theory	45
Figure 9:	The “gut-lymph” theory	47
Figure 10:	Graphical representation of the three-dimensional backbone structures of FABPs.....	60
Figure 11:	Comparison between patients group and control group as regards serum IFABP level on day one.	77
Figure 12:	Comparison between patients group and control group as regards serum IFABP level on day ten.....	77
Figure 13:	Serum IFABP on day 1 and day 10 for all patients included in the study.....	78
Figure 14:	Box plot showing the BUN level between patients received lactoferrin and patients who did not on day ten (D10) in the study.	86

List of Figures *cont...*

Fig. No.	Title	Page No.
Figure 15:	Fate of patients receiving lactoferrin and patients who not receiving.	88
Figure 16:	Box plot showing the SOFA score between patients who are receiving lactoferrin on day one (D1) and day ten(D10)in the study.....	91
Figure 17:	Box plot showing the serum creatinine level between patients who are receiving lactoferrin on day one (D1) and day ten(D10)in the study.....	93
Figure 18:	Box plot showing the PH level between patients who are receiving lactoferrin on day one (D1) and day ten(D10)in the study.....	93
Figure 19:	Box plot showing the SOFA score results between survivors and non-survivors on day one (D1)	97
Figure 20:	Comparison between Survivors and non survivors patients as regards POC2 level I n day one of the study.....	99
Figure 21:	Results of serum lactate between two studied groups on day one of the study.	99
Figure 22:	Box plot showing the serum IFABP results between survivors and non-survivors	100
Figure 23:	Relation between GIF score result and fate	101
Figure 24:	Results of culture and sensitivity among survivors and non-survivors.....	102
Figure 25:	Receiver-operating characteristic (ROC) curve analysis for prediction of mortality using SOFA score and serum IFABP level results on day one of the study.	104

List of Abbreviations

Abb.	Full term
<i>AGI</i>	<i>Acute gastrointestinal injury</i>
<i>APACHE II</i>	<i>Acute Physiology and chronic Health evaluation II</i>
<i>bLF</i>	<i>Bovine lactoferrin</i>
<i>CARS</i>	<i>Compensatory anti-inflammatory reaction</i>
<i>CCK1</i>	<i>Cholecystokinin</i>
<i>CIPOs</i>	<i>Chronic intestinal pseudo-obstructions</i>
<i>CT</i>	<i>Computed tomography</i>
<i>ELISA</i>	<i>Enzyme-linked immunosorbent assay</i>
<i>GI</i>	<i>Gastrointestinal</i>
<i>hLF</i>	<i>Human lactoferrin</i>
<i>HS</i>	<i>Highly significant</i>
<i>IAH</i>	<i>Intra abdominal hemorage</i>
<i>IAP</i>	<i>Intra abdominal pressure</i>
<i>ICUs</i>	<i>Intensive care units</i>
<i>IF</i>	<i>Intestinal failure</i>
<i>IF</i>	<i>Intestinal failure</i>
<i>I-FABP</i>	<i>Intestinal fatty acid binding protein</i>
<i>LF</i>	<i>Lactoferrin</i>
<i>LOS</i>	<i>Length of stay</i>
<i>l-FABP</i>	<i>Liver fatty acid-binding protein</i>

List of Abbreviations cont...

Abb.	Full term
<i>LIFE</i>	<i>Lausanne Intestinal Failure Estimation</i>
<i>MODS</i>	<i>Multiple organ dysfunction syndrome</i>
<i>MOF</i>	<i>Multiple organ failure</i>
<i>MRSA</i>	<i>Meticillin resistant Staphylococcus aureus</i>
<i>NMR</i>	<i>Nuclear magnetic resonance</i>
<i>NS</i>	<i>Non significant</i>
<i>NOMI</i>	<i>Non occlusive mesenteric infarction</i>
<i>PELOD</i>	<i>Pediatric logistic organ dysfunction score</i>
<i>PICUs</i>	<i>Paediatric intensive care units</i>
<i>PMODS</i>	<i>Pediatric Multiple Organ Dysfunction Score</i>
<i>PN</i>	<i>Parenteral nutrition</i>
<i>PNALD</i>	<i>Parenteral nutrition associated liver disease</i>
<i>S</i>	<i>Significant</i>
<i>SBS</i>	<i>Short bowel syndrome</i>
<i>SIRS</i>	<i>Systemic inflammatory response syndrome</i>
<i>SOFA</i>	<i>Sequential Organ Failure Assessment</i>
<i>SPROUT</i>	<i>Sepsis Prevalence, Outcomes, and Therapies</i>

INTRODUCTION

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. For clinical operationalization, organ dysfunction can be represented by an increase in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more, which is associated with an in-hospital mortality greater than 10%. Septic shock should be defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. Patients with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia. This combination is associated with hospital mortality rates greater than 40% (*Singer et al., 2016*).

In critically ill patients, the intestine is a vulnerable organ, and gastrointestinal (GI) dysfunction is common. Conversely, GI dysfunction can indicate a critical condition. It has been reported that almost 50% of patients in intensive care units (ICUs) have enterocyte damage at admission. Among critically ill patients, those with GI dysfunction have higher mortality rates than those without GI dysfunction. It is therefore important to monitor the status of the GI tract in critically ill patients (*Li et al., 2017*).